MedTrace Logo

Primary Aldosteronism: Prospective Screening Registry in China

NCT04020783 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10000

Last updated 2024-08-13

No results posted yet for this study

Summary

1. Study name: A prospective study of the incidence and outcomes of Primary aldosteronism in Chinese hypertensive patients
2. Rationale: Unlike essential hypertension, secondary hypertension is caused by certain defined diseases or causes. For this reason, secondary hypertension can often be cured or effectively controlled. As one of the most common types of secondary hypertension, it is estimated that primary aldosteronism (PA) accounts for 5%-10% of all hypertensive patients, accounting for about 20% of patients with refractory hypertension.
3. Objective: 1) Collect and analyze the population and disease characteristics of Chinese PA patients; 2) Strengthen the awareness of screening for PA in people with high blood pressure.
4. Study design: Prospective , multi-center, observational study.
5. Study population: Hypertensive patients with high suspected or confirmed of primary aldosteronism.
6. Treatment: Standardized diagnosis and treatment procedure as recommended in the international guidelines of PA.
7. Follow up: 6, 12 and 24 months after diagnosis.
8. Sample size estimation: About 10 thousand.
9. Timeline: Start of subjects enrollment: July 2019; End of subjects enrollment: December 2022; End of study: December 2024.
10. Organization: The Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital, Shanghai, China.

Conditions

  • Primary Aldosteronism

Interventions

OTHER

NO Intervention

NO Intervention

Sponsors & Collaborators

  • Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • Jiguang Wang, MD, PhD · Shanghai Jiao Tong University School of Medicine Ruijin Hospital

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-18
Primary Completion
2024-10-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04020783 on ClinicalTrials.gov